Brief: Lumos Pharma Announces A Clinical Collaboration With Massachusetts General Hospital To Evaluate Oral LUM-201 In Nonalcoholic Fatty Liver Disease In A Phase 2 Investigator-Initiated Trial
05/05/2022 14:13
May 5 (Reuters) - Lumos Pharma Inc LUMO.O :
* LUMOS PHARMA ANNOUNCES A CLINICAL COLLABORATION WITH
MASSACHUSETTS GENERAL HOSPITAL (MGH) TO EVALUATE ORAL LUM-201 IN
NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN A PHASE 2
INVESTIGATOR-INITIATED TRIAL
Source text for Eikon: ID:nGNXbYjVwL
Further company coverage: LUMO.O
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)